Operational Summary

for the Fiscal Year Ended March 31, 2012

May 10, 2012 Mitsubishi Chemical Holdings Corporation

Table of Contents

Consolidated Financial Statements for FY2011	Page No.	Consolidated Forecasts for FY2012	Page N
Statements of Operations	4	Statements of Operations	13
Net Sales and Operating Income by Business Segment	5	Net Sales and Operating Income by Business Segment	14
Net Sales and Operating Income by "Business Sub-Segment"	6	Trend of Operating Income	15
Analysis of Operating Income (FY2010 vs.FY2011)	7	Net Sales and Operating income by "Business Sub-Segment"	16
Extraordinary Gain (Loss)	8	Analysis of Operating Income (FY2011 Actual vs.FY2012 Forecast)	17
Cash Flows Balance Sheets	9 10	Analysis of Operating Income (2H of FY2011 vs. 1H & 2H of FY2012 Forecast)	18
Statement of Changes in Net Assets	11	Cash Flows and Other Numerical Targets	19
Statements of Comprehensive Income	12	Capital Expenditure, Depreciation & Amortization, R&D Expenses, Total Assets, and Number of Employees by Business Segment	20
		Major Capital Expenditure	21
		Cash Dividends	22
		References	
		Scope of Consolidation and Overseas Sales and Operating Income	23
		Major Subsidiaries	24
		Impact of the Earthquake	25
		Trend of Financial Position	26
		Reclassification of FY2011	27

List of Abbreviations

FY2012: April 1, 2012 - March 31, 2013

1st Half ("1H") of FY2012: April 1, 2012 - Septmber 30, 2012 **2nd Half ("2H") of FY2012**: October 1, 2012 - March 31, 2013

FY2011: April 1, 2011 - March 31, 2012

1st Half ("1H") of FY2011: April 1, 2011- Septmber 30, 2011 2nd Half ("2H") of FY2011: October 1, 2011 - March 31, 2012 4th Quarter ("4Q") of FY2011: January 1, 2012- March 31, 2012

FY2010: April 1, 2010 - March 31, 2011

FY2011 Forecast: Company's forecasts for FY2011 disclosed on February 3, 2012

MCHC: Mitsubishi Chemical Holdings Corporation

MCC: Mitsubishi Chemical Corporation

MTPC: Mitsubishi Tanabe Pharma Corporation

MPI: Mitsubishi Plastics, Inc.
MRC: Mitsubishi Rayon Co., Ltd.

(Note)

Divisional numbers in the following "business sub-segments" under the business segments of Designed Materials, Health Care, Chemicals, or Polymers are approximation for reference purpose only;

Functional Products

Performance Chemicals

Pharmaceuticals

Diagnostics, Clinical Testing and API

Petrochemicals

Carbon

Polyolefins and Advanced Polymers MMA Monomers and Polymers

Consolidated Statements of Operations

Exchange rate (¥/US\$)	79.2	78.8	79.0	85.2	(6.2)	77.9
Exchange rate to translate foreign statements with calender-year accounting peirod (¥/US\$)	81.8	77.5	79.6	87.3	(7.7)	79.4
Naphtha price (¥/kl)	57,000	52,900	54,900	47,500		54,500
					(Billions of Yen)	(Reference)
			FY2011	FY2010		FY2011
	411	01.1			Change	
	1H	2H	Actual	Actual		Forecast
Net sales	1,570.2	1,638.0	3,208.2	3,166.8	41.4	3,220.0
Operating income	95.7	34.9	130.6	226.5	(95.9)	135.0
Income (expenses) on financing activities	(4.1)	(2.6)	(6.7)	(8.9)	2.2	(7.0)
[Dividend income included in above]	[2.7]	[4.3]	[7.0]	[5.0]		
Equity in Earnings of non-consolidated subsidiaries and affiliates	8.5	6.4	14.9	15.1	(0.2)	15.0
Other non-operating income (expenses)	(7.2)	2.0	(5.2)	(8.8)	3.6 b	
Ordinary income	92.9	40.7	133.6	223.9	(90.3)	132.0
Extraordinary gain	7.0	16.6	23.6	6.7	16.9	18.0
Extraordinary loss	(16.5)	(13.2)	(29.7)	(61.0)	31.3	(34.0)
Income before income taxes and minority interests	83.4	44.1	127.5	169.6	(42.1)	116.0
Current and deferred income taxes	(26.2)	(27.0)	(53.2)	(47.0)	(6.2) C	(47.0)
Income before minority interests	57.2	17.1	74.3	122.6	(48.3)	69.0
Minority interests in consolidated subsidiaries	(19.7)	(19.1)	(38.8)	(39.0)	0.2	(39.0)
Net income (loss)	37.5	(2.0)	35.5	83.6	(48.1)	30.0
	П	ı				
Comprehensive income attributable to :	60.4	3.8	64.2	86.7	(22.5)	
Shareholders of the parent	40.7	(15.4)	25.3	51.6	(26.3)	
Minority interests	19.7	19.2	38.9	35.1	3.8	

Major reasons for the change

- (a) Dividend income +2.0: Dividend income from SPDC Ltd.
- (b) Other non-operating income (expenses) +3.6: Insurance income +3.2,
- (c) Current and deferred income taxes (6.2): Expenses increased for FY2011 due to amendment of tax laws (14.9)

Consolidated Net Sales and Operating Income by Business Segment

						(Billions of Yen)	(Reference)
		1H	2H	FY2011 Actual	FY2010 Actual	Change	FY2011 Forecast
Total	Net Sales	1,570.2	1,638.0	3,208.2	3,166.8	41.4	3,220.0
Total	Operating Income	95.7	34.9	130.6	226.5	(95.9)	135.0
Electronics Applications	Net Sales	69.8	64.0	133.8	152.4	(18.6)	135.0
Electronics Applications	Operating Income	(1.2)	(4.1)	(5.3)	1.0	(6.3)	(5.0)
Designed Meterials	Net Sales	338.5	322.8	661.3	657.5	3.8	670.0
Designed Materials	Operating Income	17.3	6.7	24.0	36.5	(12.5)	23.0
Health Care	Net Sales	246.7	255.8	502.5	505.0	(2.5)	505.0
nealth Care	Operating Income	39.7	36.7	76.4	85.1	(8.7)	77.0
Chamiaala	Net Sales	466.2	541.3	1,007.5	895.4	112.1	1,000.0
Chemicals	Operating Income	19.4	(4.6)	14.8	53.0	(38.2)	20.0
Delymere	Net Sales	352.0	345.2	697.2	731.2	(34.0)	700.0
Polymers	Operating Income	23.3	2.1	25.4	55.0	(29.6)	26.0
Othoro	Net Sales	97.0	108.9	205.9	225.3	(19.4)	210.0
Others	Operating Income	1.6	4.5	6.1	4.5	1.6	3.0
Composito	Net Sales	-	-	-	-	-	-
Corporate	Operating Income	(4.4)	(6.4)	(10.8)	(8.6)	(2.2)	(9.0)
mpact of the earthquake	est of the couthwister	(14.6)	(3.0)	(17.6)	1.7	(19.3)	(17.4)
Operating income exclud. impa	ict of the earthquake	110.3	37.9	148.2	224.8	(76.6)	152.4

Consolidated Net Sales and Operating Income by "Business Sub-segment"

						(Billions of Yer	n)	(Reference)
			1H	2H	FY2011 Actual	FY2010 Actual	Change		FY2011 Forecast
	ectronics Applications	Net Sales	69.8	64.0	133.8	152.4	(18.6)		135.0
	ectionics Applications	Operating Income	(1.2)	(4.1)	(5.3)	1.0	(6.3)	а	(5.0)
	Functional Products*	Net Sales	235.0	224.0	459.0	448.0	11.0		460.0
Designed Materials	Functional Products	Operating Income	9.3	2.8	12.1	15.2	(3.1)	b	11.5
Desi Mate	Performance Chemicals*	Net Sales	103.5	98.8	202.3	209.5	(7.2)		210.0
	Performance Chemicals	Operating Income	8.0	3.9	11.9	21.3	(9.4)	С	11.5
Ф	Pharmaceuticals*	Net Sales	200.3	206.8	407.1	409.5	(2.4)		405.0
n Care	Pharmaceuticals	Operating Income	37.8	35.3	73.1	81.6	(8.5)	d	72.0
Health	Diagnostics, Clinical Testing and API*	Net Sales	46.4	49.0	95.4	95.5	(0.1)		100.0
I	Diagnostics, Clinical Testing and AFT	Operating Income	1.9	1.4	3.3	3.5	(0.2)		5.0
0	Petrochemicals*	Net Sales	329.3	407.7	737.0	656.0	81.0		730.0
Chemicals	retrochemicals	Operating Income	11.0	(9.7)	1.3	31.3	(30.0)	е	7.0
Chen	Carbon*	Net Sales	136.9	133.6	270.5	239.4	31.1		270.0
)	Carbon	Operating Income	8.4	5.1	13.5	21.7	(8.2)	f	13.0
	Polyolefins and Advanced Polymers*	Net Sales	207.2	226.1	433.3	461.4	(28.1)		440.0
Polymers	Polyoletilis allu Auvaliceu Polymers	Operating Income	3.9	(4.2)	(0.3)	18.2	(18.5)	g	0.0
Poly	MMA Monomers and Polymers*	Net Sales	144.8	119.1	263.9	269.8	(5.9)		260.0
	wima monomers and rolymers	Operating Income	19.4	6.3	25.7	36.8	(11.1)	h	26.0

^{*} Approximation for reference purpose only

Inventory valuation gain/loss	1H	2H	FY2011 Actual	FY2010 Actual	Change	FY2011 Forecast
Chemicals (Petrochemicals)	3.2	1.9	5.1	4.7	0.4	0.5
Chemicals (Carbon)	1.7	(0.4)	1.3	3.8	(2.5)	1.3
Polymers (Polyolefins and Advanced Polymers)	5.2	(0.8)	4.4	5.6	(1.2)	3.2
Total	10.1	0.7	10.8	14.1	(3.3)	5.0

Major reasons for the change

- (a) Decreased sales for display materials
- (b) Decreased sales for polyester film
- (d) Increase in SGA expenses and decrease in sales
- (e) Decreased margin for PTA and low operating rate for the No.2 PTA production facility in India
- (f) Decreased export margin for blast furnace coke
- (c) Decreased sales for OPL film and impact of the earthquake (g) Impact of the earthquake and decreased margin for polyolefin and phenol-polycarbonate chain
 - (h) Decreased demand for acrylic resin

Analysis of Operating Income (FY2010 vs. FY2011)

							(Billions of Yen)
	=>/00/4	- 3/22/42			Ana	lysis	
	FY2011 Actual	FY2010 Actual	Change	Price	Volume	Impact of the earthquake	Fixed costs and others
Total	130.6	226.5	(95.9)	(39.4)	(30.8)	(19.3)	(6.4)
Electronics Applications	(5.3)	1.0	(6.3)	(2.0)	(3.2)	(1.6)	0.5
Designed Materials	24.0	36.5	(12.5)	(4.6)	(9.0)	(1.1)	2.2
Health Care	76.4	85.1	(8.7)	0.9	4.3	(6.5)	(7.4)
Chemicals	14.8	53.0	(38.2)	(22.5)	(11.6)	(4.0)	(0.1)
Polymers	25.4	55.0	(29.6)	(11.2)	(13.1)	(5.9)	0.6
Others	6.1	4.5	1.6	-	1.8	(0.2)	0.0
Corporate	(10.8)	(8.6)	(2.2)	-	-	0.0	(2.2)

Consolidated Extraordinary Gain (Loss)

				(Billions of Yen)
		FY2011	FY2010	
	4Q	Actual	Actual	Change
Total	0.1	(6.1)	(54.3)	48.2
Extraordinary gain	6.9	23.6	6.7	16.9
Gain on forgiveness of debts	-	5.7	-	5.7
Gain on sales of investment securities	0.9	3.3	2.0	1.3
Reversal of provision for loss on disaster	3.1	3.1	-	3.1
Gain on sales of noncurrent assets	0.7	2.7	1.2	1.5
Insurance income	-	1.2	-	1.2
Others	2.2	7.6	3.5	4.1
Extraordinary loss	(6.8)	(29.7)	(61.0)	31.3
Impairment loss	(4.0)	(10.2)	(3.7)	(6.5)
Loss on sales and retirement of noncurrent assets	(3.6)	(6.0)	(12.4)	6.4
Loss on valuation of investment securities	6.1	(3.9)	(10.8)	6.9
Losses on the Great East Japan Earthquake	(1.5)	(2.3)	(22.5)	20.2
Others	(3.8)	(7.3)	(11.6)	4.3

Consolidated Cash Flows

Based on statements of cash flows

Adjusted by excluding financial investments of cash in hands

(Billions of Yen)

	FY2011 Actual	FY2010 Actual
Net cash provided by operating activities	218.0	288.9
Income before income taxes and minority interests	127.5	169.6
Depreciation and amortization	145.7	148.7
Amortization of goodwill	12.3	12.1
Change in operating receivables/payables	40.1	7.7
Change in Inventories	(33.5)	(17.4)
Others	(74.1)	(31.8)
Net cash (used in) provided by investing activities	(63.4)	(101.1)
Capital expenditure	(116.0)	(115.4)
Investment and loans receivables, etc.	52.6	14.3
Free cash flow	154.6	187.8
Net cash (used in) provided by financing activities	(164.1)	(149.5)
Interest bearing debts	(131.1)	(126.4)
Dividends, etc.	(33.0)	(23.1)
ncrease (decrease) in cash and cash equivalents	(9.5)	38.3
ash and cash equivalents at the end of the period	133.1	143.7

FY2011 Actual Excluded 57.5 billion yen	FY2010 Actual Excluded (0.8) billion yen
218.0	288.9
127.5	169.6
145.7	148.7
12.3	12.1
40.1	7.7
(33.5)	(17.4)
(74.1)	(31.8)
(120.9)	(100.3)
(116.0)	(115.4)
(4.9)	15.1
97.1	188.6

Consolidated Balance Sheets

(Bil	lions	of	Yen

	Mar. 31, 2012 Actual	Mar. 31, 2011 Actual	Change
Cash and deposits	114.8	130.2	(15.4)
Inventories	516.1	485.1	31.0
Trade receivables	593.4	597.2	(3.8)
Others	153.5	184.2	(30.7)
Current assets	1,377.8	1,396.7	(18.9)
Fixed assets	1,099.1	1,160.4	(61.3)
Goodwill	141.8	154.8	(13.0)
Investment and Others	555.3	582.1	(26.8)
Fixed assets	1,796.2	1,897.3	(101.1)
Total assets	3,174.0	3,294.0	(120.0)

(Billions of Ye

	Mar. 31, 2012 Actual	Mar. 31, 2011 Actual	Change
Interest-bearing debts	1,164.1	1,304.6	(140.5)
Trade payables	411.3	378.4	32.9
Others	453.6	497.0	(43.4)
Liabilities	2,029.0	2,180.0	(151.0)
Shareholders' equity	831.6	8.808	22.8
Accumulated other comprehensive income	(60.8)	(50.5)	(10.3)
Minorities interests, etc.	374.2	355.7	18.5
Net assets	1,145.0	1,114.0	31.0

Total liabilities and net assets	3,174.0	3,294.0	(120.0)
----------------------------------	---------	---------	---------

Interest-bearing debts (incl. notes)	1,164.5	1,304.6	(140.1)
Debt-equity ratio	1.51	1.72	(0.21)
Net interest-bearing debts (*1)	936.8	1,008.7	(71.9)
Net debt-equity ratio	1.22	1.33	(0.11)
Shareholders' equity (*2)	770.7	758.3	12.4
Shareholders' equity ratio	24.2%	23.0%	1.2%

^{*1.} Net interest-bearing debts (936.8 billion yen)

⁼ interest bearing debts, including discounted notes (1,164.5 billion yen)

^{- {}cash and cash equivalents (133.1 billion yen + financial investments of cash-in-hands (94.6 billion yen)}

^{*2.} Represents the sum of shareholders' equity and accumulated other comprehensive income per the above B/S.

Consolidated Statement of Changes in Net Assets

(Billions of Yen)

													(1)	
	Common stock	Additional paid-in capital	Retained earnings	Treasury stock at cost	Total shareholders' equity	Net unrealized holding gain (loss) on other securities	Gain (loss) on deferred hedges	Land revaluatio n surplus	Foreign currency translation adjustments	Unfunded retirement benefit obligation with respect to a foreign subsidiary	Accumulated other comprehensive income (loss)	Warrants	Minority interests in consolidated subsidiaries	Tota net assets
Beginning of period	50.0	317.6	451.9	(10.8)	808.8	5.2	(0.7)	1.4	(52.4)	(4.0)	(50.5)	0.7	355.1	1,114.0
Cash dividends			(14.8)		(14.8)						-			(14.8)
Net income			35.5		35.5						-			35.5
Purchase of treasury stock				(0.1)	(0.1)						-			(0.1)
Disposal of treasury stock		0.0		0.0	0.1						-			0.1
Increase due to merger of non-consolidated subsidiaries by consolidated subsidiaries			0.0		0.0						-			0.0
Increase due to merger of non-consolidated subsidiaries by equity-method affiliates			0.0		0.0						-			0.0
Change in scope of consolidation			1.2		1.2						-			1.2
Change in scope of equity method			0.8		0.8						-			0.8
Net change in items other than those in shareholders' equity						(0.6)	0.6	0.2	(9.6)	(0.8)	(10.3)	(0.0)	18.5	8.1
Net change during the period	-	0.0	22.8	(0.0)	22.8	(0.6)	0.6	0.2	(9.6)	(8.0)	(10.3)	(0.0)	18.5	31.0
End of period	50.0	317.6	474.8	(10.8)	831.6	4.6	(0.1)	1.6	(62.0)	(4.9)	(60.8)	0.7	373.6	1,145.0

Consolidated Statements of Comprehensive Income

		(Dec. 2010)	(Dec. 2009)
		Dec. 2011	Dec. 2010
		(81.5)	(92.1)
Exchange rate to translate foreign statements with calender-year accounting peirod	(¥/US\$)	77.7	81.5
		(107.9)	(132.0)
Exchange rate to translate foreign statements with calender-year accounting peirod	(¥/€)	100.7	107.9

(Billions of Yen)

	FY2011 Actual	FY2010 Actual	Change
Net income	35.5	83.6	(48.1)
Minority interests in consolidated subsidiaries	38.8	39.0	(0.2)
Income before minority interests	74.3	122.6	(48.3)
Other comprehensive income (loss):			
Net unrealized holding gain (loss) on other securities	0.7	(6.5)	7.2
Gain (loss) on deferred hedges	1.2	(1.0)	2.2
Foreign currency translation adjustments	(10.3)	(25.0)	14.7
Unfunded retirement benefit obligation with respect to a foreign subsidiary	(0.8)	(8.0)	0.0
Other comprehensive income (loss) for affiliates accounted for using equity method	(0.9)	(2.6)	1.7
Other comprehensive income (loss), net	(10.1)	(35.9)	25.8
Total comprehensive income (loss)	64.2	86.7	(22.5)
Total comprehensive income (loss) attributable to :			
Shareholders of the parent	25.3	51.6	(26.3)
Minority interests	38.9	35.1	3.8

Consolidated Statement of Operations (FY2012 Forecast)

Forecast

Exchange rate (¥/US\$)	79.2	78.8	79.0	81.0	81.0	81.0	2.0
Exchange rate to translate foreign statements with calender-year accounting peirod (¥/US\$)	81.8	77.5	79.6	81.6	81.0	81.3	1.7
Naphtha price (¥/kl)	57,000	52,900	54,900	62,000	62,000		7,100
							(Billions of Yen
						1	
			FY2011			FY2012	Change
	1H	2H	Actual	1H	2H	Forecast	Onlange
Net sales	1,570.2	1,638.0	3,208.2	1,653.0	1,797.0	3,450.0	241.8
Operating income	95.7	34.9	130.6	52.0	108.0	160.0	29.4
Income (expenses) on financing activities	(4.1)	(2.6)	(6.7)	(5.0)	(4.0)	(9.0)	(2.3)
[Dividend income included in above]	[2.7]	[4.3]	[7.0]	[2.0]	[3.0]	[5.0]	[(2.0)]
Equity in Earnings of non-consolidated subsidiaries and affiliates	8.5	6.4	14.9	6.0	6.0	12.0	(2.9)
Other non-operating income (expenses)	(7.2)	2.0	(5.2)	(8.0)	(7.0)	(15.0)	(9.8)
Ordinary income	92.9	40.7	133.6	45.0	103.0	148.0	14.4
Extraordinary gain	7.0	16.6	23.6	2.0	1.0	3.0	(20.6)
Extraordinary loss	(16.5)	(13.2)	(29.7)	(10.0)	(14.0)	(24.0)	5.7
Income before income taxes and minority interests	83.4	44.1	127.5	37.0	90.0	127.0	(0.5)
Current and deferred income taxes	(26.2)	(27.0)	(53.2)	(14.0)	(28.0)	(42.0)	11.2
Income before minority interests	57.2	17.1	74.3	23.0	62.0	85.0	10.7
Minority interests in consolidated subsidiaries	(19.7)	(19.1)	(38.8)	(12.0)	(23.0)	(35.0)	3.8
Net income (loss)	37.5	(2.0)	35.5	11.0	39.0	50.0	14.5

Consolidated Net Sales and Operating Income by Business Segment (FY2012 Forecast)

(Billions of Yen)

		1H	2H	FY2011 Actual	1H	2H	FY2012 Forecast	Change
Total	Net Sales	1,570.2	1,638.0	3,208.2	1,653.0	1,797.0	3,450.0	241.8
	Operating Income	95.7	34.9	130.6	52.0	108.0	160.0	29.4
Electronics Applications	Net Sales	69.8	64.0	133.8	65.0	80.0	145.0	11.2
Electronics Applications	Operating Income	(1.2)	(4.1)	(5.3)	(2.0)	2.0	0.0	5.3
Designed Meterials	Net Sales	355.0	344.9	699.9	370.0	400.0	770.0	70.1
Designed Materials	Operating Income	17.2	5.9	23.1	12.0	21.0	33.0	9.9
Hoolth Care	Net Sales	246.7	255.8	502.5	253.0	277.0	530.0	27.5
Health Care	Operating Income	39.7	36.7	76.4	32.0	47.0	79.0	2.6
Chamicala	Net Sales	466.2	541.3	1,007.5	475.0	510.0	985.0	(22.5)
Chemicals	Operating Income	19.4	(4.6)	14.8	7.0	22.0	29.0	14.2
Delymere	Net Sales	335.5	323.1	658.6	390.0	420.0	810.0	151.4
Polymers	Operating Income	22.3	1.5	23.8	7.0	17.0	24.0	0.2
Othoro	Net Sales	97.0	108.9	205.9	100.0	110.0	210.0	4.1
Others	Operating Income	1.6	4.5	6.1	1.0	3.0	4.0	(2.1)
Corporate	Net Sales	-	-	-	-	-	-	-
Corporate	Operating Income	(3.3)	(5.0)	(8.3)	(5.0)	(4.0)	(9.0)	(0.7)

Impact of the earthquake


Operating income exclud. impact of the earthquake

Γ	(14.6)	(3.0)	(17.6)	-	-	-	
t	110.3	37.9	148.2	52.0	108.0	160.0	11.8

Segmentation changes effective from fiscal 2012:

¹⁴

Trend of Operating Income



Note: 'Performance Products' represent the Electronics Applications segment and the Designed Materials segment. 'Industrial Materials' represent the Chemicals segment and the Polymers segment.

Consolidated Net Sales and Operating Income by "Business Sub-segment" (FY2012 Forecast)

(Billions of Yen)


								,	
			1H	2H	FY2011 Actual	1H	2H	FY2012 Forecast	Change
	actronica Annlications	Net Sales	69.8	64.0	133.8	65.0	80.0	145.0	11.2
	ectronics Applications	Operating Income	(1.2)	(4.1)	(5.3)	(2.0)	2.0	0.0	5.3
0	Functional Products*	Net Sales	251.5	246.1	497.6	255.0	275.0	530.0	32.4
Designed Materials	Functional Products	Operating Income	9.2	2.0	11.2	5.0	9.5	14.5	3.3
Designed Materials	Performance Chemicals*	Net Sales	103.5	98.8	202.3	115.0	125.0	240.0	37.7
		Operating Income	8.0	3.9	11.9	7.0	11.5	18.5	6.6
ē	Pharmaceuticals*	Net Sales	200.3	206.8	407.1	203.0	226.0	429.0	21.9
, Care		Operating Income	37.8	35.3	73.1	30.0	44.5	74.5	1.4
Health (Diagnostics, Clinical Testing and API*	Net Sales	46.4	49.0	95.4	50.0	51.0	101.0	5.6
エ		Operating Income	1.9	1.4	3.3	2.0	2.5	4.5	1.2
"	Datrockomicals*	Net Sales	329.3	407.7	737.0	355.0	385.0	740.0	3.0
Chemicals	Petrochemicals*	Operating Income	11.0	(9.7)	1.3	1.0	11.0	12.0	10.7
her	Carbon*	Net Sales	136.9	133.6	270.5	120.0	125.0	245.0	(25.5)
	Carbon*	Operating Income	8.4	5.1	13.5	6.0	11.0	17.0	3.5
	Polyolofine and Advanced Polymere*	Net Sales	190.7	204.0	394.7	245.0	265.0	510.0	115.3
mers	Polyolefins and Advanced Polymers*	Operating Income	2.9	(4.8)	(1.9)	1.0	6.0	7.0	8.9
Polymers	MMA Monomore and Polymore*	Net Sales	144.8	119.1	263.9	145.0	155.0	300.0	36.1
	MMA Monomers and Polymers*	Operating Income	19.4	6.3	25.7	6.0	11.0	17.0	(8.7)

^{*} Approximation for reference purpose only

FY2012 vs. FY2011


Inventory valuation gain/loss	1H	2H	FY2011 Actual	1H	2H	FY2012 Forecast	Change
Chemicals (Petrochemicals)	3.2	1.9	5.1	0.3	0.7	1.0	(4.1)
Chemicals (Carbon)	1.7	(0.4)	1.3	1.3	0.0	1.3	0.0
Polymers(Polyolefins and Advanced Polymers)	5.2	(0.8)	4.4	4.4	0.5	4.9	0.5
Total	10.1	0.7	10.8	6.0	1.2	7.2	(3.6)

Analysis of Operating Income (FY2011 Actual vs. FY2012 Forecast)



Analysis of Operating Income (2H of FY2011 vs. 1H & 2H of FY2012 Forecast)

Forecast





Consolidated Cash Flows and Other Numerical Targets

Adjusted by excluding financial investments of cash in hands

(Rillions of Yen)

		(Billions of Yen)
	FY2012 Target	FY2011 Actual
Net cash provided by operating activities	228.0	218.0
Income before income taxes and minority interests	127.0	127.5
Depreciation and amortization	136.0	145.7
Amortization of goodwill	12.0	12.3
Change in working capital	(24.0)	6.6
Others	(23.0)	(74.1)
Net cash used in investing activities	(123.0)	(120.9)
Capital expenditures	(140.0)	(116.0)
Investment and loans receivables, etc.	17.0	(4.9)
Free cash flow	105.0	97.1

Financial indices

Net profit per share (Yen)

	March 31, 2013 Target	March 31, 2012 Actual	Change
Net interest-bearing debts (Billion of Yen)	869.0	936.8	(67.8)
Net debt-equity ratio	1.08	1.22	(0.14)
Shareholders' equity (Billion of Yen)	804.0	770.7	33.3
	FY2012 Target	FY2011 Actual	Change
EBITDA*1 (Billion of Yen)	308.0	288.6	19.4
Net income (Rillion of Yen)	50.0	35.5	14.5

¥33.91

¥9.85

¥24.06

^{*1} EBITDA = Operating income + Depreciation + Amortization (including goodwill)

Consolidated Capital Expenditure, Depreciation & Amortization, R&D Expenses, Total Assets, and Number of Employees by Business Segment Forecast

(Billions of yen, untill otherwise noted)

	Capital Ex	penditure	Depreci Amorti	iation & ization	R&D Expenses			Total Assets	Number of Employees
	FY2012 Forecast	FY2011 Actual	FY2012 Forecast	FY2011 Actual	FY2012 Forecast	FY2011 Actual		FY2011 Actual	FY2011 Actual
Electronics Applications	7.0	6.2	7.0	7.9	9.0	9.8		123.4	3,245
Designed Materials	62.0	49.5	48.0	49.2	25.0	24.0		720.9	14,394
Health Care	17.0	11.8	15.0	18.0	81.0	78.7		852.3	12,860
Chemicals	22.0	24.5	28.0	33.0	6.0	5.4		656.0	5,178
Polymers	23.0	18.1	32.0	32.0	15.0	14.9		714.6	7,369
Others	4.0	4.6	4.0	3.8	1.0	0.5		295.8	9,988
Corporate	5.0	1.4	2.0	1.8	6.0	5.2	•	(189.0)	945
Total	140.0	116.1	136.0	145.7	143.0	138.5		3,174.0	53,979

Segmentation changes effective from fiscal 2012:

Some consolidated subsidiaries in the Polymers segment will be transferred to the Designed Materials segment.

Part of expenses for basic research activities in the Corporate segment will be transferred to the Designed Materials segment, as a result of progress in the research. In associated with these changes, fiscal 2011 results have been reclassified for comparison with fiscal 2012 forecasts, except for total assets and number of employees.



Major Capital Expenditure

	Major new and additional facilities completed during FY2011				Major facilities under construction					
	Company	Name of project	Completion date	Capacity increase	Company	Name of project	Planned completion date	Capacity increase		
	MCC Sakaide Plant	Production facility for anode for lithium-ion battery (addition)	May 2011	2,000t/y	The Nippon Synthetic Chemical Industry Co., Ltd. Kumamoto Plant	Production facility for Polyvinyl alcohol film (addition)	1Q of FY2012	15 million m [*] /y		
	Qingdao Anode Kasei Co., Ltd.	Production facility for anode for lithium-ion battery (new)	Oct. 2011	4,000t/y	MC Ionic Solutions UK Ltd.(UK)	Production facility for electrolyte for lithium- ion battery (new)	Apr. 2012	10,000t/y		
Designed Materials	MPI Sakaide Plant	Production facility for alumina fiber (additon)	Jan. 2012	400t/y	MC Ionic Solutions US Ltd.(US)	Production facility for electrolyte for lithium- ion battery (new)	May 2012	10,000t/y		
	MRC Otake Plant	Production facility for carbon fiber (addition)	Jun. 2011	2,700t/y	MPI Sakaide Plant	Production facility for alumina fiber (additon)	May 2012 Dec. 2012	800t/y		
	-				Mitsubishi Polyester Film Suzhou Co., Ltd.	Production facility for polyester film (new)	Apr. 2013 Apr. 2015	45,000t/y		
Health Care	Mitsubishi Tanabe Pharma Factory Ltd. Kashima Plant	Production facility for pharmaceutical products (new)	Feb. 2012	-		_				
nealth Care	Benesis Corporation Kyoto Plant	Production facility for pharmaceutical products (new)	Mar. 2012	-		-				
	MCC Sakaide Plant	Coke oven gas desulfurization equipment (new)	Dec. 2011	-	P. T. Mitsubishi Chemical Indonesia	Electric source conversion	Dec. 2012	-		
Chemicals	MCC Sakaide Plant	Coke oven dust collection system and other (renovation)	Apr. 2011	-		_				
	MCC Kurosaki Plant	Power equipment (rationalization)	Oct. 2011	-						
Polymers	MRC Otake Plant	Production facility for Acrylic sheet (enhancement)	Jun. 2011	-	Lucite International (US)	Production facility for MMA monomer (improvement)	Apr. 2012	-		
i olymers		-	Lucite International (US)	Production facility for Methacrylic Acid (new)	4Q of FY2012	23,000t/y				

Cash Dividends

		FY2012 Forecast	FY2011 Actual	FY2010 Actual	FY2009 Actual	FY2008 Actual
	1st Half	6	5	5	4	8
Cash dividends per share (Yen)	Year end	6	5	5	4	4
	Total	12	10	10	8	12
	1st Half		7.4	6.9	5.5	11.0
Cash dividends (Billions of yen)	Year end		7.4	7.4	5.5	5.5
	Total		14.8	14.3	11.0	16.5
Net profit per share (Yen)	Year end	¥33.91	¥24.06	¥58.72	¥9.32	(¥48.81)
Dividend pay out ratio (Consolidated)	-	35.4%	41.6%	17.0%	85.8%	-

MCHC's basic policy is to distribute dividends based on consolidated business results, while simultaneously retaining of sufficient internal reserves for the future business developments and stable dividends over medium-to-long terms. For fiscal 2012, we plan an annual dividend of ¥12 per share.

Scope of Consolidation and Overseas Sales and Operating Income

Reference

(Number of affiliates)

Scope of consolidation	FY2011	FY2010	FY2009	FY2008	FY2007
Total	404	411	421	240	260
Consolidated subsidiaries	341	341	345	177	189
Japan	130	127	129	95	106
Overseas	211	214	216	82	83
Affiliates accounted for by the equity method	63	70	76	63	71

Net sales and operating income by geographic area based on location of consolidated subsidiaries

(Billions of Yen)

Japan	2,352.5	2,436.8	2,116.4	2,477.4	2,420.6
Overseas	855.7	730.0	398.7	431.6	509.2
Net sales	3,208.2	3,166.8	2,515.1	2,909.0	2,929.8
Japan	72.6	153.2	44.9	11.7	126.8
Overseas	58.0	73.3	21.4	(3.5)	(1.8)
Operating income	130.6	226.5	66.3	8.2	125.0

Overseas sales

(Billions of Yen)

Overseas sales	1,184.4	1,087.6	637.2	668.1	795.4
	36.9%	34.3%	25.3%	22.9%	27.1%

Major Subsidiaries

		Net Sales		Operating Income					
Company				(Billions of Yer					
(Consolidated)	FY2011	FY2010	Change	FY2011	FY2010	Change			
MCC	2,080.9	2,019.6	61.3	23.1	88.1	(65.0)			
MTPC	407.2	409.5	(2.3)	69.0	76.6	(7.6)			
MPI	379.0	382.0	(3.0)	10.6	16.6	(6.0)			
MRC	474.0	478.4	(4.4)	30.3	41.0	(10.7)			
Adjustments*	(132.9)	(122.7)	(10.2)	(2.4)	4.2	(6.6)			
мснс	3,208.2	3,166.8	41.4	130.6	226.5	(95.9)			

^{*}Adjustments for MCHC consolidation

- Those for net sales represent elimination of internal transactions.
- Those for operating income represent primarily amortization of goodwill as well as elimination of internal transactions.



Reference

Impact of the Earthquake


0 al .7	4Q (1.4) 3.1 3.1	FY2011 Actual (17.6)	Loss (Sum of the two years) (15.9)	Insuranse income - 3.1 3.1 1.2	Accumulated net impact for the two years (15.9) a 3.1 3.1 4.3
-	3.1	3.1	3.1	3.1	3.1 3.1
- - - -				3.1	3.1
<u>-</u> - -					
-				1.2	4.3
_	2.4				
	3.1	3.1	3.1	-	3.1
-	-	-	-	1.2	1.2
.5)	(1.5)	(6.9)	(29.4)	4.6	(24.8)
.5)	(1.5)	(6.9)	(29.4)	-	(29.4)
-	-	-	-	4.6	4.6
					<u>a+b+c+d</u>
.8)	0.2	(21.4)	(42.2)	8.9	(33.3)
2. 0.	2.5) 2.5) -	2.5) (1.5) 	2.5) (1.5) (6.9) 	2.5) (1.5) (6.9) (29.4) 0.8) 0.2 (21.4) (42.2) eact for FY2011 (12.5) Excluding	2.5) (1.5) (6.9) (29.4) 2.5) (1.5) (6.9) (29.4) - - - 4.6 0.8) 0.2 (21.4) (42.2) 8.9




Reference

Trend of Financial Position

Net Assets, Shareholders' equity, Interest-bearing debt (Billions of yen)



Ratio of shareholders' equity to total assets Debt-equity ratio Net debt-equity ratio



Net debt-equity ratio is calculated as (a - (b + c)) / d

- (a) interest bearing debts including discounted notes
- (b) cash and cash equivalents
- (c) financial investments of cash-in-hands
- (d) the sum of shareholders' equity and accumulated other comprehensive income.



Reference

Reclassification of FY2011

Segmentation changes effective from fiscal 2012:

Some consolidated subsidiaries in the Polymers segment will be transferred to the Designed Materials segment.

Part of expenses for basic research activities in the Corporate segment will be transferred to the Designed Materials segment, as a result of progress in the research.

In associated with these changes, fiscal 2011 results have been reclassified for comparison with fiscal 2012 forecasts.

				Α			В			(Billions of Yen) A+B
		1H	2H	FY2011	1H	2H	Reclassifi- cation	1H	2H	Reclassified FY2011
Designed Materials	Net Sales	338.5	322.8	661.3	16.5	22.1	38.6	355.0	344.9	699.9
	Operating Income	17.3	6.7	24.0	(0.1)	(8.0)	(0.9)	17.2	5.9	23.1
Performance Chemicals*	Net Sales	235.0	224.0	459.0	16.5	22.1	38.6	251.5	246.1	497.6
	Operating Income	9.3	2.8	12.1	(0.1)	(0.8)	(0.9)	9.2	2.0	11.2
Dolumoro	Net Sales	352.0	345.2	697.2	(16.5)	(22.1)	(38.6)	335.5	323.1	658.6
Polymers	Operating Income	23.3	2.1	25.4	(1.0)	(0.6)	(1.6)	22.3	1.5	23.8
Polyclofine and Advanced Polymore*	Net Sales	207.2	226.1	433.3	(16.5)	(22.1)	(38.6)	190.7	204.0	394.7
Polyolefins and Advanced Polymers*	Operating Income	3.9	(4.2)	(0.3)	(1.0)	(0.6)	(1.6)	2.9	(4.8)	(1.9)
Cornorato	Net Sales	-	-	-	-	-	-	-	-	-
Corporate	Operating Income	(4.4)	(6.4)	(10.8)	1.1	1.4	2.5	(3.3)	(5.0)	(8.3)

^{*} Approximation for reference purpose only

The forward-looking statements are based largely on company expectations and information available as of the date hereof, and are subject to risks and uncertainties, which may be beyond company control.

Actual results could differ materially due to numerous factors, including without limitation, marketing conditions and the effects of industry competition.